Molecular biology of familial and sporadic vestibular schwannomas: Implications for novel therapeutics. A review

Journal of Neurosurgery

Volumn 114, Issue 2, 2011, Pages 359-366

  Sughrue, Michael E ^a   Yeung, Andrea H ^a   Rutkowski, Martin J ^a   Cheung, Steven W ^a   Parsa, Andrew T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Merlin; Neurofibromatosis type 2; Vestibular schwannoma

Indexed keywords

ANGIOGENIC FACTOR; COMPLEMENTARY DNA; GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MERLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CELL MOTILITY; CELL PROLIFERATION; CHROMOSOME; CORRELATION ANALYSIS; DNA LIBRARY; GENE FUNCTION; GENE MUTATION; GENOTYPE; HUMAN; MOLECULAR BIOLOGY; MORBIDITY; MOSAICISM; NEURILEMOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

HUMANS; MUTATION; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC;

EID: 79551694041     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.10.JNS091135     Document Type: Review

References (74)

1. Abaza MM, Makariou E, Armstrong M, Lalwani AK: Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 106:694-699, 1996 (Pubitemid 26184043)
2. Adams EF, Rafferty B, Mower J, Ward H, Petersen B, Fahlbusch R: Human acoustic neuromas secrete interleukin-6 in cell culture: possible autocrine regulation of cell proliferation. Neurosurgery 35:434-438, 1994 (Pubitemid 24275766)
3. Baser ME, R Evans DG, Gutmann DH: Neurofibromatosis 2. Curr Opin Neurol 16:27-33, 2003 (Pubitemid 36206759)
4. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N: The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol 22:1150-1157, 2002 (Pubitemid 34094851)
5. Bikhazi PH, Lalwani AK, Kim EJ, Bikhazi N, Attaie A, Slattery WH, et al: Germline screening of the NF-2 gene in families with unilateral vestibular schwannoma. Otolaryngol Head Neck Surg 119:1-6, 1998 (Pubitemid 28350657)
6. Bretscher A, Edwards K, Fehon RG: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586-599, 2002
7. Bruder CE, Hirvelä C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, et al: High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 10:271-282, 2001 (Pubitemid 32140315)
8. Cardillo MR, Filipo R, Monini S, Aliotta N, Barbara M: Transforming growth factor-beta1 expression in human acoustic neuroma. Am J Otol 20:65-68, 1999 (Pubitemid 29180059)
9. Cayé-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE: Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113:2129-2134, 2003 (Pubitemid 38063834)
10. Charabi S, Engel P, Charabi B, Jacobsen GK, Overgaard J, Thomsen J, et al: Growth of vestibular schwannomas: in situ model employing the monoclonal antibody Ki-67 and DNA flow cytometry. Am J Otol 17:301-306, 1996 (Pubitemid 26171774)
11. Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, et al: The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 23:281-282, 1998 (Pubitemid 28461889)
12. Diensthuber M, Brandis A, Lenarz T, Stöver T: Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma. Otol Neurotol 25:359-365, 2004 (Pubitemid 39079821)
13. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al: A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 29:847-852, 1992 (Pubitemid 23035206)
14. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, et al: A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841-846, 1992 (Pubitemid 23035205)
15. Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, et al: Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31:354-362, 2002 (Pubitemid 35154443)
16. Ferner RE, O'Doherty MJ: Neurofibroma and schwannoma. Curr Opin Neurol 15:679-684, 2002 (Pubitemid 35471675)
17. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
18. Ford HL, Pardee AB: Cancer and the cell cycle. J Cell Biochem Suppl 32-33:166-172, 1999 (Pubitemid 30041823)
19. Gary R, Bretscher A: Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell 6:1061-1075, 1995
20. Gusella JF, Ramesh V, MacCollin M, Jacoby LB: Neurofibromatosis 2: loss of merlin's protective spell. Curr Opin Genet Dev 6:87-92, 1996 (Pubitemid 26059057)
21. Gutmann DH, Giordano MJ, Fishback AS, Guha A: Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 49:267-270, 1997 (Pubitemid 27328718)
22. Gutmann DH, Hirbe AC, Haipek CA: Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet 10:1519-1529, 2001 (Pubitemid 32684894)
23. Halum SL, Erbe CB, Friedland DR, Wackym PA: Gene discovery using a human vestibular schwannoma cDNA library constructed from a patient with neurofibromatosis type 2 (NF2). Otolaryngol Head Neck Surg 128:364-371, 2003 (Pubitemid 36351049)
24. Halum SL, Popper P, Cioffi JA, Wackym PA: Serial analysis of gene expression in neurofibromatosis type 2-associated vestibular schwannoma. Otol Neurotol 25:587-593, 2004 (Pubitemid 39079784)
25. Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca EA: Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 91:85-92, 1999
26. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER: Molecular genetic analysis of the mechanism of tumorigenesis in acoustic neuroma. Arch Otolaryngol Head Neck Surg 119:1222-1228, 1993 (Pubitemid 23339139)
27. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER: Somatic NF2 gene mutations in familial and nonfamilial vestibular schwannoma. Hum Mol Genet 3:347-350, 1994 (Pubitemid 24060955)
28. Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS: Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol 29:58-68, 2008
29. Jacoby LB, Jones D, Davis K, Kronn D, Short MP, Gusella J, et al: Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 61:1293-1302, 1997 (Pubitemid 28046905)
30. Jacoby LB, MacCollin M, Louis DN, Mohney T, Rubio MP, Pulaski K, et al: Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 3:413-419, 1994 (Pubitemid 24083900)
31. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al: NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29:4250-4261, 2009
32. Jin H, Sperka T, Herrlich P, Morrison H: Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442:576-579, 2006 (Pubitemid 44167917)
33. Kley N, Seizinger BR: The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Cancer Surv 25:207-218, 1995 (Pubitemid 26065314)
34. Klinken L, Thomsen J, Rasmussen BB, Wiet RJ, Tos M: Estrogen and progesterone receptors in acoustic neuromas. Arch Otolaryngol Head Neck Surg 116:202-204, 1990 (Pubitemid 20051853)
35. Kluwe L, Mautner VF: Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 7:2051-2055, 1998 (Pubitemid 28546413)
36. LaJeunesse DR, McCartney BM, Fehon RG: Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol 141:1589-1599, 1998 (Pubitemid 28309173)
37. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI: NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090-1100, 2003 (Pubitemid 36534984)
38. Lanser MJ, Sussman SA, Frazer K: Epidemiology, pathogenesis, and genetics of acoustic tumors. Otolaryngol Clin North Am 25:499-520, 1992
39. Lasak JM, Welling DB, Akhmametyeva EM, Salloum M, Chang LS: Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope 112:1555-1561, 2002 (Pubitemid 34977553)
40. Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, et al: Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 45:1709-1720, 2009
41. Lesser TH, Janzer RC, Kleihues P, Fisch U: Clinical growth rate of acoustic schwannomas: correlation with the growth fraction as defined by the monoclonal antibody ki-67. Skull Base Surg 1:11-15, 1991
42. Lim JY, Kim H, Jeun SS, Kang SG, Lee KJ: Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun 340:1151-1157, 2006 (Pubitemid 43083399)
43. Lutchman M, Rouleau GA: Neurofibromatosis type 2: a new mechanism of tumor suppression. Trends Neurosci 19:373-377, 1996 (Pubitemid 26270512)
44. MacCollin M, Braverman N, Viskochil D, Ruttledge M, Davis K, Ojemann R, et al: A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol 40:440-445, 1996 (Pubitemid 26304801)
45. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, et al: Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845, 2005
46. Mawrin C, Kirches E, Dietzmann K, Roessner A, Boltze C: Expression pattern of apoptotic markers in vestibular schwannomas. Pathol Res Pract 198:813-819, 2002 (Pubitemid 36221703)
47. Monoh K, Ishikawa K, Yasui N, Mineura K, Andoh H, Togawa K: p53 tumor suppressor gene in acoustic neuromas. Acta Otolaryngol Suppl 537:11-15, 1998 (Pubitemid 28545369)
48. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968-980, 2001 (Pubitemid 32323547)
49. Nair SB, Leung HY, Ince P, Ramsden RT, Wilson JA: Fibroblast growth factor receptor expression investibular schwannoma. Clin Otolaryngol Allied Sci 25:570-576, 2000
50. O'Reilly B, Murray CD, Hadley DM: The conservative management of acoustic neuroma: a review of forty-four patients with magnetic resonance imaging. Clin Otolaryngol Allied Sci 25:93-97, 2000
51. O'Reilly BF, Kishore A, Crowther JA, Smith C: Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas. Otol Neurotol 25:791-796, 2004 (Pubitemid 39223258)
52. Obremski VJ, Hall AM, Fernandez-Valle C: Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol 37:487-501, 1998 (Pubitemid 28549213)
53. Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K: Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res 69:4043-4051, 2009
54. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450-461, 1994 (Pubitemid 24298996)
55. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, Halpin C, Padera TP, Tyrrell A, et al: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367, 2009
56. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515-521, 1993 (Pubitemid 23186636)
57. Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger BR, et al: Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329:246-248, 1987 (Pubitemid 17128967)
58. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180-184, 1994 (Pubitemid 24188600)
59. Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, et al: Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 110:2249-2260, 1997 (Pubitemid 27448369)
60. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM: Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3:885-891, 1994 (Pubitemid 24189953)
61. Sakuda K, Kohda Y, Matsumoto T, Park C, Seto A, Tohma Y, et al: Expression of NF2 gene product merlin in arachnoid villi and meningiomas. Noshuyo Byori 13:145-148, 1996
62. Schulze KM, Hanemann CO, Müller HW, Hanenberg H: Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 11:69-76, 2002 (Pubitemid 34100769)
63. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, et al: Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 11:3179-3189, 2002 (Pubitemid 35439430)
64. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60:3689-3695, 2000
65. Sughrue ME, Yang I, Aranda D, Lobo K, Pitts LH, Cheung SW, et al: The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. Clinical article. J Neurosurg. Published online ahead of print June 19, 2009. DOI: 10.3171/2009.4.JNS08895
66. Szeremeta W, Monsell EM, Rock JP, Caccamo DV: Proliferation indices of vestibular schwannomas by Ki-67 and proliferating cell nuclear antigen. Am J Otol 16:616-619, 1995
67. Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H: An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269:23387-23390, 1994
68. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al: A novel moesin-, ezrin, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75:826, 1993 (Erratum)
69. Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, et al: Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. J Med Genet 40:802-806, 2003 (Pubitemid 37485489)
70. Welling DB, Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, et al: Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 98:189-193, 1996 (Pubitemid 26237502)
71. Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 23:736-748, 2002
72. Wiet RJ, Ruby SG, Bauer GP: Proliferating cell nuclear antigen in the determination of growth rates in acoustic neuromas. Am J Otol 15:294-298, 1994 (Pubitemid 24164934)
73. Xiao GH, Chernoff J, Testa JR: NF2: the wizardry of merlin. Genes Chromosomes Cancer 38:389-399, 2003 (Pubitemid 37466941)
74. Zang KD: Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 6:249-274, 1982